Overview

The Vienna Prograf and Endothelial Progenitor Cell Study

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine if the conversion from the immunosuppressive agent cyclosporine to tacrolimus contributes to an improvement of the cardiovascular risk factors, better kidney function and immune system.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of Vienna
Treatments:
Cyclosporine
Cyclosporins
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus